Open AccessIn Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model
Author(s) -
Yufeng Zhou,
Ping Liu,
Shu-He Dai,
Jian Sun,
Yahong Liu,
XiaoPing Liao
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01354-20
Subject(s) - streptococcus pneumoniae , staphylococcus aureus , in vivo , pneumonia , microbiology and biotechnology , pharmacodynamics , antibiotics , staphylococcal infections , antibacterial agent , medicine , biology , bacteria , pharmacology , pharmacokinetics , genetics
We determined in vivo efficacy and target PK/PD exposures of antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in the murine pneumonia model. The mean plasma free drug area under the concentration-time curve/MIC ( f AUC/MIC) targets associated with stasis and 1-log 10 and 2-log 10 kill effects were 8.93, 19.2, and 48.1, respectively, for S. pneumoniae , whereas they were 30.5, 55.4, and 115.8, respectively, for S. aureus The f AUC/MIC targets in murine lung epithelial lining fluids (ELF) for the same endpoints were nearly 2-fold higher than those in plasma.